Yvette W Jeske1, Shamshad Ali2, Sara A Byron3, Feng Gao4, Robert S Mannel5, Rahel G Ghebre6, Paul A DiSilvestro7, Shashikant B Lele8, Michael L Pearl9, Amy P Schmidt10, Heather A Lankes2, Nilsa C Ramirez11, Golnar Rasty12, Matthew Powell10, Paul J Goodfellow13, Pamela M Pollock14. 1. Queensland University of Technology (QUT) at the Translational Research Institute, Brisbane, Australia. 2. NRG Oncology Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, NY, USA. 3. Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA. 4. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA. 5. Gynecologic Oncology, The Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 6. University of Minnesota Medical Center - Fairview, Minneapolis, MN, USA. 7. Gynecologic Oncology, Women and Infants Hospital, Providence, RI, USA. 8. Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA. 9. Obstetrics and Gynecology, Stony Brook University Hospital, Stony Brook, NY, USA. 10. Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, MO, USA. 11. GOG Tissue Bank/NRG Oncology Biospecimen Bank - Columbus, Biopathology Center, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. 12. Department of Laboratory Medicine, University of Toronto, ON, M5G2C, CANADA. 13. Department of Obstetrics and Gynecology, The Ohio State University and James Comprehensive Cancer Center, Columbus, OH, USA. 14. Queensland University of Technology (QUT) at the Translational Research Institute, Brisbane, Australia; Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA. Electronic address: pamela.pollock@qut.edu.au.
Abstract
PURPOSE: Activating FGFR2 mutations have been identified in ~10% of endometrioid endometrial cancers (ECs). We have previously reported that mutations in FGFR2 are associated with shorter disease free survival (DFS) in stage I/II EC patients. Here we sought to validate the prognostic importance of FGFR2 mutations in a large, multi-institutional patient cohort. METHODS: Tumors were collected as part of the GOG 210 clinical trial "Molecular Staging of Endometrial Cancer" where samples underwent rigorous pathological review and had more than three years of detailed clinical follow-up. DNA was extracted and four exons encompassing the FGFR2 mutation hotspots were amplified and sequenced. RESULTS: Mutations were identified in 144 of the 973 endometrioid ECs, of which 125 were classified as known activating mutations and were included in the statistical analyses. Consistent with FGFR2 having an association with more aggressive disease, FGFR2 mutations were more common in patients initially diagnosed with stage III/IV EC (29/170;17%) versus stage I/II EC (96/803; 12%; p=0.07, Chi-square test). Additionally, incidence of progression (progressed, recurred or died from disease) was significantly more prevalent (32/125, 26%) among patients with FGFR2 mutation versus wild type (120/848, 14%; p<0.001, Chi-square test). Using Cox regression analysis adjusting for known prognostic factors, patients with FGFR2 mutation had significantly (p<0.025) shorter progression-free survival (PFS; HR 1.903; 95% CI 1.177-3.076) and endometrial cancer specific survival (ECS; HR 2.013; 95% CI 1.096-3.696). CONCLUSION: In summary, our findings suggest that clinical trials testing the efficacy of FGFR inhibitors in the adjuvant setting to prevent recurrence and death are warranted.
PURPOSE: Activating FGFR2 mutations have been identified in ~10% of endometrioid endometrial cancers (ECs). We have previously reported that mutations in FGFR2 are associated with shorter disease free survival (DFS) in stage I/II EC patients. Here we sought to validate the prognostic importance of FGFR2 mutations in a large, multi-institutional patient cohort. METHODS:Tumors were collected as part of the GOG 210 clinical trial "Molecular Staging of Endometrial Cancer" where samples underwent rigorous pathological review and had more than three years of detailed clinical follow-up. DNA was extracted and four exons encompassing the FGFR2 mutation hotspots were amplified and sequenced. RESULTS: Mutations were identified in 144 of the 973 endometrioid ECs, of which 125 were classified as known activating mutations and were included in the statistical analyses. Consistent with FGFR2 having an association with more aggressive disease, FGFR2 mutations were more common in patients initially diagnosed with stage III/IV EC (29/170;17%) versus stage I/II EC (96/803; 12%; p=0.07, Chi-square test). Additionally, incidence of progression (progressed, recurred or died from disease) was significantly more prevalent (32/125, 26%) among patients with FGFR2 mutation versus wild type (120/848, 14%; p<0.001, Chi-square test). Using Cox regression analysis adjusting for known prognostic factors, patients with FGFR2 mutation had significantly (p<0.025) shorter progression-free survival (PFS; HR 1.903; 95% CI 1.177-3.076) and endometrial cancer specific survival (ECS; HR 2.013; 95% CI 1.096-3.696). CONCLUSION: In summary, our findings suggest that clinical trials testing the efficacy of FGFR inhibitors in the adjuvant setting to prevent recurrence and death are warranted.
Authors: Michael Meyer; Anna-Katharina Müller; Jingxuan Yang; Daniel Moik; Gilles Ponzio; David M Ornitz; Richard Grose; Sabine Werner Journal: J Cell Sci Date: 2012-09-19 Impact factor: 5.285
Authors: Amy E Merrill; Anna Sarukhanov; Pavel Krejci; Brian Idoni; Natalia Camacho; Kristine D Estrada; Karen M Lyons; Hannah Deixler; Haynes Robinson; David Chitayat; Cynthia J Curry; Ralph S Lachman; William R Wilcox; Deborah Krakow Journal: Am J Hum Genet Date: 2012-03-01 Impact factor: 11.025
Authors: Elena López-Knowles; Silvia Hernández; Núria Malats; Manolis Kogevinas; Josep Lloreta; Alfredo Carrato; Adonina Tardón; Consol Serra; Francisco X Real Journal: Cancer Res Date: 2006-08-01 Impact factor: 12.701
Authors: Gonzalo Recondo; Enrique Dìaz Canton; Màximo de la Vega; Martin Greco; Gonzalo Recondo; Matias E Valsecchi Journal: World J Clin Oncol Date: 2014-08-10
Authors: Amit M Oza; Laurie Elit; Ming-Sound Tsao; Suzanne Kamel-Reid; Jim Biagi; Diane Michele Provencher; Walter H Gotlieb; Paul J Hoskins; Prafull Ghatage; Katia S Tonkin; Helen J Mackay; John Mazurka; Joana Sederias; Percy Ivy; Janet E Dancey; Elizabeth A Eisenhauer Journal: J Clin Oncol Date: 2011-07-25 Impact factor: 44.544
Authors: Yuchen Jiao; Timothy M Pawlik; Robert A Anders; Florin M Selaru; Mirte M Streppel; Donald J Lucas; Noushin Niknafs; Violeta Beleva Guthrie; Anirban Maitra; Pedram Argani; G Johan A Offerhaus; Juan Carlos Roa; Lewis R Roberts; Gregory J Gores; Irinel Popescu; Sorin T Alexandrescu; Simona Dima; Matteo Fassan; Michele Simbolo; Andrea Mafficini; Paola Capelli; Rita T Lawlor; Andrea Ruzzenente; Alfredo Guglielmi; Giampaolo Tortora; Filippo de Braud; Aldo Scarpa; William Jarnagin; David Klimstra; Rachel Karchin; Victor E Velculescu; Ralph H Hruban; Bert Vogelstein; Kenneth W Kinzler; Nickolas Papadopoulos; Laura D Wood Journal: Nat Genet Date: 2013-11-03 Impact factor: 38.330
Authors: Leisl M Packer; Samantha J Stehbens; Vanessa F Bonazzi; Jennifer H Gunter; Robert J Ju; Micheal Ward; Michael G Gartside; Sara A Byron; Pamela M Pollock Journal: Mol Oncol Date: 2019-01-18 Impact factor: 6.603
Authors: Marianna A Zolotovskaia; Maxim I Sorokin; Ivan V Petrov; Elena V Poddubskaya; Alexey A Moiseev; Marina I Sekacheva; Nicolas M Borisov; Victor S Tkachev; Andrew V Garazha; Andrey D Kaprin; Peter V Shegay; Alf Giese; Ella Kim; Sergey A Roumiantsev; Anton A Buzdin Journal: Int J Mol Sci Date: 2020-02-26 Impact factor: 5.923